Key result
Edoxaban is noninferior to warfarin for stroke and systemic embolism prevention and reduces cardiovascular mortality, but increases gastrointestinal bleeding.
Why the study?
Does edoxaban reduce stroke and systemic embolism compared to warfarin and other NOACs in adults with nonvalvular atrial fibrillation?
Meta-Analysis (n=23,021)
Does edoxaban reduce stroke and systemic embolism compared to warfarin and other NOACs in adults with nonvalvular atrial fibrillation?
Edoxaban is noninferior to warfarin for stroke prevention in nonvalvular atrial fibrillation and reduces cardiovascular mortality and major bleeding, though it increases the risk of gastrointestinal bleeding and anemia.
Answers are grounded in this paper and cite their sources.
Edoxaban provides a practical option versus warfarin in nonvalvular AF; extends pooled RCT evidence while leaving head-to-head data versus other NOACs open.
BACKGROUND: A critical appraisal of all pooled evidence regarding novel oral anticoagulants (NOACs) for stroke prevention regardless of publication status or study design has not been conducted yet. Being the latest addition to NOACs, the data on edoxaban are especially scarce. STUDY QUESTION: What are the comparative clinical outcomes of edoxaban versus warfarin and other NOACs apixaban, dabigatran, or rivaroxaban in adults with nonvalvular atrial fibrillation? DATA SOURCES: Randomized controlled trials (RCTs), observational studies, and network meta-analyses were identified in PubMed, EMBASE, the Cochrane Library, Pharmapendium, Elsevier Clinical Pharmacology, and the clinicaltrials.gov trial registry in June 2018. STUDY DESIGN: Rapid review per a priori developed protocol, direct frequentist random-effects meta-analysis of aggregate data, grading the quality of evidence per the Grading of Recommendations Assessment, Development and Evaluation working group approach. RESULTS: Direct 4 RCTs (23,021 patients) suggest that edoxaban is noninferior to warfarin in prevention of stroke and systemic embolism [pooled relative risk (RR): 0.65, 95% confidence interval (CI): 0.23-1.81, 2 RCTs] and reduces the risk of cardiovascular mortality (RR: 0.87, 95% CI: 0.78-0.97, 1 RCT), major cardiovascular morbidity (RR: 0.90, 95% CI: 0.82-0.98, 2 RCTs), and major bleeding events (RR: 0.80, 95% CI: 0.71-0.91, 1 RCT) but increases the risk of gastrointestinal bleeding (RR: 1.21, 95% CI: 1.01-1.46, 1 RCT) and anemia (RR: 1.45, 95% CI: 1.05-1.99, 3 RCTs). Edoxaban is superior to warfarin in patients with increased risk of bleeding with warfarin because of variants in CYP2C9 and VKORC1 genes. Indirect evidence does not allow valid conclusions regarding comparative superiority of NOACs. The quality of evidence was downgraded because of reporting bias, small number of events, and indirectness in comparisons. CONCLUSIONS: Edoxaban is a welcome addition to the NOAC's armamentarium. However, the comparative data with other novel NOACs are mostly nonexisting, and urgently needed for better individual patient assessment.
No takes yet. Share an insight, caveat, or question.
Aronow et al. (2018) conducted a meta-analysis in nonvalvular atrial fibrillation (n=23,021). Edoxaban vs. Warfarin was evaluated on stroke and systemic embolism (RR 0.65, 95% CI 0.23-1.81). Edoxaban is noninferior to warfarin for stroke and systemic embolism prevention and reduces cardiovascular mortality, but increases gastrointestinal bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: